Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Given Consensus Rating of “Buy” by Analysts

Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) have been assigned an average rating of “Buy” from the six research firms that are presently covering the stock, Marketbeat reports. Six investment analysts have rated the stock with a buy rating. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $21.00.

A number of brokerages have commented on ARTV. HC Wainwright began coverage on Artiva Biotherapeutics in a research report on Monday, December 30th. They issued a “buy” rating and a $20.00 price objective for the company. Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 price target on shares of Artiva Biotherapeutics in a report on Wednesday, November 13th.

Institutional Investors Weigh In On Artiva Biotherapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. BNP Paribas Financial Markets acquired a new stake in shares of Artiva Biotherapeutics in the 3rd quarter valued at $42,000. MetLife Investment Management LLC acquired a new position in shares of Artiva Biotherapeutics during the third quarter worth about $135,000. JPMorgan Chase & Co. acquired a new position in shares of Artiva Biotherapeutics during the third quarter worth about $166,000. Barclays PLC acquired a new position in shares of Artiva Biotherapeutics during the third quarter worth about $304,000. Finally, Charles Schwab Investment Management Inc. acquired a new position in shares of Artiva Biotherapeutics during the third quarter worth about $623,000.

Artiva Biotherapeutics Trading Down 4.6 %

Shares of NASDAQ ARTV opened at $6.25 on Friday. The firm’s 50-day moving average is $10.39. Artiva Biotherapeutics has a 52 week low of $6.19 and a 52 week high of $17.31.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its earnings results on Tuesday, November 12th. The company reported ($0.92) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.24). Research analysts expect that Artiva Biotherapeutics will post -4.95 earnings per share for the current year.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.